论文部分内容阅读
肿瘤坏死因子相关的诱导配体为近年来新发现的凋亡调节的重要蛋白之一。死亡受体5（DR5）为其诱导凋亡的重要受体之一。 DR5的结构、组织分布及其可诱导肿瘤细胞凋亡而不影响正常细胞的特性，已成为近年的研究热点。其中 DR5单克隆抗体应用于耐药卵巢癌细胞的治疗，为耐药卵巢癌细胞治疗提供了新的思路。该文将 DR5单克隆抗体应用于卵巢癌耐药的研究进展予以综述。“,”Tumor necrosis factor-related inducing ligand is one of the recently discovered important pro-teins for the apoptosis regulation.Death receptor ( DR5) is one of the important receptor for induction of apoptosis.DR5 structure, tissue distribution and the feature of inducing apoptosis in cancer cells without affecting normal cells,have become the hot topics in recent years.DR5 monoclonal antibody used in the treat-ment of drug-resistant ovarian cancer cells has provided a new way of thinking for the treatment of drug-resist-ant ovarian cancer,and here is to make a review of the studies on DR5 monoclonal antibodies applied to the drug-resistant ovarian cancer.